StreetInsider.com News Articles

Form NT 20-F Alps Group Inc For: Mar 31

Fri, 31 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260731/26851191.html

Form NT 20-F Alps Group Inc For: Mar 31

Fri, 31 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260731/26851191.html

Form 6-K Alps Group Inc For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679465.html

Alps Group launches patient-derived organoid cancer program in Malaysia

Tue, 23 Jun 2026 08:05:56 -0400

Alps Group Inc (Nasdaq: ALPS), a biotechnology company based in Malaysia, announced a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech, to launch a patient-derived organoid (PDO) program targeting personalized cancer treatment and preclinical drug screening.

Under the agreement, Alps aims to develop what it describes as Malaysia's first clinically validated PDO platform, with plans to seek MREC ethics approval and Medical Device Authority regulatory registration to support clinical deployment and commercialization.

PDO technology involves growing three-dimensional structures from a patient's own cancer tissue to evaluate how individual tumors may respond to different therapies. Alps stated

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

Tue, 23 Jun 2026 08:05:00 -0400

Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform

KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development.

Under the agreement, Alps is launching an internal PDO

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

Tue, 23 Jun 2026 08:05:00 -0400

Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform

Under the agreement, Alps is launching an internal PDO

Form 6-K Alps Group Inc For: Jun 09

Tue, 09 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260609/26621235.html

MyGenome receives accreditation for whole genome sequencing services

Tue, 09 Jun 2026 08:05:47 -0400

Alps Group Inc (NASDAQ: ALPS) announced that its subsidiary MyGenome Sdn. Bhd. received accreditation for whole genome sequencing under MS ISO 15189:2022 standards.

The MS ISO 15189:2022 standard establishes quality and competence requirements for medical laboratories. The accreditation allows MyGenome to perform whole genome sequencing, which examines a patient's complete DNA sequence, rather than targeted genetic panels.

According to the company, the accreditation places MyGenome among a select group of genomics laboratories in Southeast Asia operating whole genome sequencing under this international standard. The certification confirms that MyGenome's genomic data meets accuracy, reproducibility and reliability requirements for clinical use and research programs.

"Expanding

Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022

Tue, 09 Jun 2026 08:05:00 -0400

MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics

KUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its subsidiary, MyGenome Sdn. Bhd. (“MyGenome”), has received accreditation for its Whole Genome Sequencing (“WGS”) under MS ISO 15189:2022.

MS ISO 15189:2022 is an internationally recognized clinical standard that sets rigorous requirements for quality and competence in medical laboratories. Unlike targeted genetic panels, WGS examines

Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022

Tue, 09 Jun 2026 08:05:00 -0400

MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics

MS ISO 15189:2022 is an internationally recognized clinical standard that sets rigorous requirements for quality and competence in medical laboratories. Unlike targeted genetic panels, WGS examines

Form 6-K Alps Group Inc For: May 19

Tue, 19 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260519/26521334.html

Form 3 Alps Group Inc For: Apr 17 Filed by: Lee Hee Hang

Mon, 20 Apr 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260420/26338097.html

Form 6-K Alps Group Inc For: Apr 17

Fri, 17 Apr 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260417/26328250.html

Alps Group names former Ernst & Young partner to board of directors

Fri, 17 Apr 2026 08:31:27 -0400

Alps Group Inc announced the appointment of Hee H. Lee to its board of directors, effective April 17, 2026. The biotechnology company's board will expand from five to six directors with this addition.

Lee brings over 35 years of experience in public accounting and advisory services, including his tenure as a partner at Ernst & Young LLP within its Global Financial Services Organization. At EY, he established and led the Americas Financial Accounting Advisory Services practice within the financial services sector.